These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37301375)

  • 21. Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in Hospitalized Patients With Diabetes.
    Petite SE; Hill MC
    Ann Pharmacother; 2021 Nov; 55(11):1326-1332. PubMed ID: 33615832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diabetes medications and associations with Covid-19 outcomes in the N3C database: A national retrospective cohort study.
    Bramante CT; Johnson SG; Garcia V; Evans MD; Harper J; Wilkins KJ; Huling JD; Mehta H; Alexander C; Tronieri J; Hong S; Kahkoska A; Alamgir J; Koraishy F; Hartman K; Yang K; Abrahamsen T; Stürmer T; Buse JB;
    PLoS One; 2022; 17(11):e0271574. PubMed ID: 36395143
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Choosing Dipeptidyl Peptidase-4 Inhibitors, Sodium-glucose Cotransporter-2 Inhibitors, or Both, as Add-ons to Metformin: Patient Baseline Characteristics Are Crucial.
    Goldenberg RM
    Clin Ther; 2017 Dec; 39(12):2438-2447. PubMed ID: 29174215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
    Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic Therapy of Type 2 Diabetes.
    Wright JJ; Tylee TS
    Med Clin North Am; 2016 Jul; 100(4):647-63. PubMed ID: 27235609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq.
    Nafakhi H; Alareedh M; Al-Buthabhak K; Shaghee F; Nafakhi A; Kasim S
    Diabetes Metab Syndr; 2021; 15(1):33-38. PubMed ID: 33296788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prior treatment with dipeptidyl peptidase 4 inhibitors is associated with better functional outcome and lower in-hospital mortality in patients with type 2 diabetes mellitus admitted with acute ischaemic stroke.
    Tziomalos K; Bouziana SD; Spanou M; Kostaki S; Papadopoulou M; Giampatzis V; Dourliou V; Kostourou DT; Savopoulos C; Hatzitolios AI
    Diab Vasc Dis Res; 2015 Nov; 12(6):463-6. PubMed ID: 26297528
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prescription patterns and therapeutic effects of second-line drugs in Japanese patients with type 2 diabetes mellitus: Analysis of claims data for metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycemic agents.
    Nishimura R; Takeshima T; Iwasaki K; Aoi S
    Expert Opin Pharmacother; 2023 Jun; 24(8):969-976. PubMed ID: 37096493
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
    Noh Y; Jeon SM; Shin S
    Int J Cancer; 2019 Apr; 144(7):1530-1539. PubMed ID: 30229901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Toyama T; Oshima M; Jun M; Chin KL; Hawley CM; Zoungas S
    Cochrane Database Syst Rev; 2020 Jul; 8(8):CD009966. PubMed ID: 32803882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.
    Thein D; Christiansen MN; Mogensen UM; Bundgaard JS; Rørth R; Madelaire C; Fosbøl EL; Schou M; Torp-Pedersen C; Gislason G; Køber L; Kristensen SL
    Cardiovasc Diabetol; 2020 Jul; 19(1):107. PubMed ID: 32631337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.
    Wu D; Li L; Liu C
    Diabetes Obes Metab; 2014 Jan; 16(1):30-7. PubMed ID: 23803146
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS; Seoane-Vazquez E; Rodriguez-Monguio R
    BMC Health Serv Res; 2018 Feb; 18(1):78. PubMed ID: 29391064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose adjustment of metformin and dipeptidyl-peptidase IV inhibitors in diabetic patients with renal dysfunction.
    Melzer-Cohen C; Karasik A; Leuschner PJ; Azuri J; Shalev V; Chodick G
    Curr Med Res Opin; 2018 Oct; 34(10):1849-1854. PubMed ID: 29611727
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
    Scheen AJ
    Diabetes Metab; 2012 Apr; 38(2):89-101. PubMed ID: 22197148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Angiotensin-Converting Enzyme (ACE) level, but not ACE gene polymorphism, is associated with prognosis of COVID-19 infection: Implications for diabetes and hypertension.
    Elbasan O; Bayram F; Yazan CD; Apaydın T; Dashdamirova S; Polat H; Arslan E; Yılmaz İ; Karimi N; Şengel BE; Yılmaz SS; Çelik ÖF; Ata P; Haklar G; Gözü H
    PLoS One; 2023; 18(7):e0288338. PubMed ID: 37432962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. All-cause mortality of insulin plus dipeptidyl peptidase-4 inhibitors in persons with type 2 diabetes.
    Yen FS; Chiang JH; Hwu CM; Yen YH; Lin BJ; Wei JC; Hsu CC
    BMC Endocr Disord; 2019 Jan; 19(1):3. PubMed ID: 30611254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.